Navigation Links
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
Date:2/27/2009

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium -

MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral, pan-Bcl-2 inhibitor currently in double-blinded, randomized Phase II clinical trials in both prostate cancer and non-small cell lung cancer, is the lead compound in Ascenta Therapeutics' portfolio of apoptosis-triggering small molecules.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873 )

"This is the first report of several we plan to present this year from a large and growing data set demonstrating the broad therapeutic potential of AT-101," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "The evidence of resistance reversal from this refractory population supplements the earlier clinical data demonstrating robust activity with the same regimen in docetaxel-naive patients."

Initial findings from the ongoing open-label, multi-center study demonstrates that AT-101 can be administered safely with D/P in these patients. Investigators also observed clinical responses, based on both PSA and RECIST criteria, including four patients with a confirmed PR (partial response, defined as a PSA decline of 50 percent or greater).

"This first look at the data is very encouraging, particularly since all of these patients were truly refractory to docetaxel, having not simply failed to respond but actually experienced disease progression during prior therapy," said James Reeves, MD, principal investigator, Florida Cance
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
2. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 A new report by ... type, Form, End user, Application and Geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", considers ... on key trends tracked, it is anticipated that the ... by 2020, registering a CAGR of 6.2% from 2014 ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
... Bulletin Board: CVBT) today announces that its,first US site ... clinical,trial for the treatment of severe coronary heart disease. ... they open for,enrollment. For current details about the clinical ... http://www.cvbt.com ., In this Phase II trial, ...
... BOSTON, Sept. 8 FluoroPharma, Inc. announced ... Chief Scientific Advisor,will report on two preclinical ... Tomography (PET) molecular imaging agents for detection,of ... the World Molecular,Imaging Congress, in Nice, France ...
Cached Medicine Technology:CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... can worsen the impact of asthma and may also mask ... Zealand, who studied lung function in asthmatic women with a ... first prospective study to reveal a significant comparative difference in ... attack in obese and non-obese individuals. , The research ...
... Trust, Inc.,(NYSE: BMR ), a real estate investment trust focused ... results for,the first quarter ended March 31, 2008., Highlights:, ... million, or $0.46 per diluted share, ... share, equivalent to an annualized common stock ...
... Brookdale Senior,Living Inc. (NYSE: BKD ) announced ... financial results after the market closes on Wednesday, May ... discuss the results on,Thursday, May 8, 2008 at 8:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069 ...
... 30 New data is showing a dramatic,reduction ... in this country.,Here,s more on one group,s 20-year ... to this report from Safe Kids Worldwide at:, ... audio, text, graphics and,photos for free and unrestricted ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... in relapsing remitting illness , , WEDNESDAY, April 30 (HealthDay ... people with the relapsing remitting form of multiple sclerosis ... the disease were randomly selected to receive either 20 ... for 24 weeks. MRI brain scans were conducted every ...
Cached Medicine News:Health News:Obesity worsens impact of asthma 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 13Health News:Brookdale Announces First Quarter 2008 Release and Earnings Call 2Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard knife with box, C profile...
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
Medicine Products: